Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bandyopadhyay, S.
Right arrow Articles by O'Mahony, M.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bandyopadhyay, S.
Right arrow Articles by O'Mahony, M.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2001; 94: 127-132
© 2001 Association of Physicians

Age and gender bias in statin trials

S. Bandyopadhyay, A.J. Bayer and M.S. O'Mahony

From the University Department of Geriatric Medicine, Llandough Hospital, Penarth, UK

Received 19 September 2000 and in revised form 19 December 2000

Cardiovascular disease is strongly age-related, and is the leading cause of death in older people. Several well-publicized trials have recently reported that statin drugs (HMG CoA reductase inhibitors) are effective in lowering cholesterol and in reducing the risk of myocardial infarction and stroke. In order to determine whether the results of these trials are relevant to our ageing population, we examined the representation of older people and women in randomized controlled trials of statin drugs. A systematic search of the medical literature from 1990 to 1999 was done to identify randomized placebo-controlled trials of statin drugs which evaluated clinical end-points—myocardial infarction, stroke or death. We identified 19 trials: 15 secondary prevention and four primary prevention. The mean age, age range and gender of the participants in these trials were determined. In the secondary prevention trials, the total number of patients randomized was 31683, with a combined mean age of 58.1 years. No trial enrolled people beyond the age of 75 years, and only 23% of the trial population was female. The four primary prevention trials randomized a combined total of 14 557 subjects with a mean age of 56.9 years. Only 10% of study participants were female. Statin drug trials have suffered from age and gender bias, having been mainly conducted in middle-aged male populations. The extrapolation of evidence from these trials to older people and women needs further evaluation.

Address correspondence to Dr M.S. O'Mahony, University Department of Geriatric Medicine, 3rd Floor, Academic Centre, Llandough Hospital, Penlan Road, Penarth CF64 2XX


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
I. Karp, S.-F. Chen, and L. Pilote
Sex differences in the effectiveness of statins after myocardial infarction
Can. Med. Assoc. J., January 30, 2007; 176(3): 333 - 338.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C Bartlett, P Davey, P Dieppe, L Doyal, S Ebrahim, and M Egger
Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001
Heart, March 1, 2003; 89(3): 327 - 328.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.